×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Osteoarthritis Therapeutics Market Share

ID: MRFR/Pharma/1078-HCR
90 Pages
Rahul Gotadki
February 2026

Osteoarthritis Market Research Report Information By Type (Hip Osteoarthritis, and Spinal Osteoarthritis), By Diagnosis (Imagining, and Joint Fluid Analysis), By Treatment (Medication, Surgery, Therapy), By End-User (Hospitals, and Medical Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Osteoarthritis Market Infographic
Purchase Options

Market Share

Osteoarthritis Market Share Analysis

Payment processors and healthcare companies can make more money by doing things other than what they normally do. When looking for new ways to make money, they could, for instance, focus on healthcare technology and services. To grow, many healthcare groups depended on slow or spontaneous changes. For example, putting more attention on healthcare areas that aren't essential could speed up progress in the future; early data shows that spending money on these areas can pay off. The ability to diversify can assist businesses in starting up new ones. Some examples are payers becoming more involved in care management to better deal with population risk, or providers adding digital services (such as telemedicine or technology-enabled care management) to connect with patients better and adapt to changes in how care is provided. Globalization helps companies get more customers, hire new workers, make more money, and bring in more cash. Getting a business started in a new market can cost a lot, so businesses think carefully about where they are now before making a plan to expand internationally. As a result, companies carefully study the rules of each new market before choosing if it makes sense to do business there. In order to help people with osteoarthritis deal with their symptoms and slow down the disease's progression, scientists are working harder to make medicines. To help patients in the long run, treatments that deal with the causes of inflammation and repair of cartilage are used. Because it can make it easier for more people to get high-quality healthcare, improve worker health and output, and lead to better results, digital health is essential. Patient engagement tools, telemedicine platforms, and mobile apps can all help patients get real-time information and manage their arthritis symptoms. The latest arthritis apps are starting to include functions that are good for the earth. This means making things in eco-friendly ways, properly throwing away trash, and trying to make treatments for osteoarthritis less harmful to the environment. The toughness of a delivery network is measured by how quickly it can fix issues and perform normally again. One way to do this is to make sure that supply chain problems don't happen too often and aren't too bad when they do. A lot of the supply chain can be affected by operational risk and uncertainty, which can finally weaken the company. Disasters on a global scale, like the COVID-19 spread, can have a big effect on job markets, suppliers, and the supply chain operations. There may be problems in the supply chain if there is quick competition, changes in the market, or even changes in the way people buy things. The most adaptable and strong supply networks can't just fix themselves when they get broken. They can see ahead and act quickly on any chances or dangers that might come up in the future thanks to the advanced supply chain technologies and processes that were used to build them. Digital tools that help companies understand and evaluate Big Data make their supply lines much more reliable. Computer programs that use AI can combine various sets of data from inside and outside the business. You can look at news stories, sales records, competitor behavior, and even notes from customers all at the same time to spot patterns and opportunities.

Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Leave a Comment

FAQs

What is the current valuation of the Osteoarthritis Market as of 2024?

<p>The Osteoarthritis Market was valued at 5.12 USD Billion in 2024.</p>

What is the projected market size for the Osteoarthritis Market in 2035?

<p>The market is projected to reach 13.37 USD Billion by 2035.</p>

What is the expected CAGR for the Osteoarthritis Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Osteoarthritis Market during this period is 9.12%.</p>

Which companies are the key players in the Osteoarthritis Market?

<p>Key players include Pfizer, Johnson & Johnson, Novartis, and AbbVie, among others.</p>

How is the Osteoarthritis Market segmented by type of osteoarthritis?

<p>The market segments include Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Spinal Osteoarthritis.</p>

What were the valuations for Knee Osteoarthritis in 2024 and its projected value in 2035?

<p>Knee Osteoarthritis was valued at 1.54 USD Billion in 2024 and is projected to reach 4.05 USD Billion by 2035.</p>

What are the projected values for pharmacological treatment in the Osteoarthritis Market?

<p>Pharmacological treatment was valued at 1.54 USD Billion in 2024 and is expected to reach 3.92 USD Billion by 2035.</p>

How does the market perform in terms of severity levels of osteoarthritis?

The market segments by severity include Mild, Moderate, and Severe Osteoarthritis, with Moderate Osteoarthritis projected to grow significantly.

What is the market outlook for older adults suffering from osteoarthritis?

The segment for older adults was valued at 3.07 USD Billion in 2024 and is projected to reach 8.98 USD Billion by 2035.

What treatment types are included in the Osteoarthritis Market segmentation?

The market is segmented into Pharmacological Treatment, Non-Pharmacological Treatment, Surgical Treatment, and Rehabilitation.

Market Summary

As per MRFR analysis, the Osteoarthritis Market size was valued at USD 5.12 Billion in 2024. The market is projected to grow from USD 5.58 Billion in 2025 to USD 13.37 Billion by 2035, exhibiting a CAGR of 9.12% during the forecast period 2025–2035.North America dominated the Osteoarthritis Therapeutics Market with the largest revenue share of 50.78% in 2024.

Key Market Trends & Highlights

The Osteoarthritis Market is experiencing transformative growth driven by innovative treatment approaches and demographic shifts.

  • The rise of biologics and targeted therapies is reshaping treatment paradigms in the Osteoarthritis Market. Personalized treatment approaches are gaining traction, particularly in North America, where patient-centric care is prioritized. Integration of digital health solutions is enhancing patient engagement and monitoring, especially in the Asia-Pacific region. The aging population and rising obesity rates are significant drivers propelling market expansion, particularly in pain management and hospital segments.

Market Size & Forecast

2024 Market Size 5.12 (USD Billion)
2035 Market Size 13.37 (USD Billion)
CAGR (2025 - 2035) 9.12%
Largest Regional Market Share in 2024 North America

Major Players

<a href="https://www.pfizer.com/news/articles/the_facts_about_osteoarthritis">Pfizer </a>(US), Johnson &amp; Johnson (US), <a href="https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-lna043-osteoarthritis-knee">Novartis </a>(CH), Bristol-Myers Squibb (US), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Roche (CH)

Market Trends

The Osteoarthritis Market is currently experiencing notable transformations driven by various factors. Increasing awareness regarding joint health and the rising prevalence of osteoarthritis among aging populations are contributing to a heightened demand for effective treatment options. Furthermore, advancements in medical technology and the development of innovative therapies are reshaping the landscape of this market.

Pharmaceutical companies are focusing on research and development to introduce novel drugs and biologics that target the underlying causes of osteoarthritis, rather than merely alleviating symptoms. This shift towards more comprehensive treatment approaches appears to be a pivotal trend in the Osteoarthritis Market. In addition, the growing emphasis on personalized medicine is influencing treatment strategies, as healthcare providers seek to tailor interventions to individual patient needs.

The integration of digital health solutions, such as telemedicine and mobile health applications, is also gaining traction, enabling patients to manage their conditions more effectively. As the Osteoarthritis Market evolves, stakeholders must remain vigilant to emerging trends and adapt their strategies accordingly to meet the changing demands of patients and healthcare systems.

Rise of Biologics and Targeted Therapies

The Osteoarthritis Market is witnessing a shift towards biologics and targeted therapies that aim to address the root causes of the condition. These innovative treatments focus on modulating the immune response and promoting cartilage repair, potentially offering more effective solutions compared to traditional pain management approaches.

Personalized Treatment Approaches

There is a growing trend towards personalized treatment strategies in the Osteoarthritis Market. Healthcare providers are increasingly recognizing the importance of tailoring interventions based on individual patient profiles, which may enhance treatment efficacy and improve patient outcomes.

Integration of Digital Health Solutions

The incorporation of digital health technologies is transforming the Osteoarthritis Market. Telemedicine and mobile applications are becoming essential tools for patient management, allowing for better monitoring of symptoms and facilitating communication between patients and healthcare professionals.

Osteoarthritis Market Market Drivers

Market Growth Projections

The Global Osteoarthritis Market Industry is poised for substantial growth, with projections indicating a market size of 5.12 USD Billion in 2024 and an anticipated increase to 13.4 USD Billion by 2035. This growth trajectory suggests a robust demand for osteoarthritis treatments and management solutions.
 
The compound annual growth rate (CAGR) of 9.12% from 2025 to 2035 reflects the increasing recognition of osteoarthritis as a significant public health issue. As stakeholders in the healthcare sector respond to this demand, the market is likely to witness innovations and enhancements in treatment options, further solidifying its growth potential.

Growing Awareness and Education

The rising awareness and education surrounding osteoarthritis are crucial drivers of the Global Osteoarthritis Market Industry. Public health campaigns and educational initiatives are increasingly informing individuals about the disease, its risk factors, and management strategies.
 
This heightened awareness encourages early diagnosis and treatment, which can lead to better health outcomes. Moreover, healthcare professionals are receiving enhanced training on osteoarthritis management, further promoting effective treatment options. As patients become more informed about their condition, they are more likely to seek medical advice and treatment, thereby driving market growth and fostering a proactive approach to managing osteoarthritis.

Increased Healthcare Expenditure

Growing healthcare expenditure across various regions is likely to bolster the Global Osteoarthritis Market Industry. As countries invest more in healthcare infrastructure and services, the availability and accessibility of osteoarthritis treatments improve. For instance, nations with higher healthcare budgets are more capable of funding advanced therapies and technologies.
 
This trend is particularly evident in developed economies, where healthcare spending is projected to rise significantly in the coming years. The increased allocation of resources towards chronic disease management, including osteoarthritis, suggests a favorable environment for market expansion, potentially leading to a compound annual growth rate (CAGR) of 9.12% from 2025 to 2035.

Advancements in Treatment Options

Innovations in treatment modalities for osteoarthritis are propelling the Global Osteoarthritis Market Industry forward. Recent developments in pharmaceuticals, biologics, and regenerative medicine offer new avenues for managing symptoms and improving patient outcomes.
 
For instance, the introduction of disease-modifying osteoarthritis drugs (DMOADs) aims to slow disease progression, which could alter the treatment landscape. Furthermore, minimally invasive surgical techniques are gaining traction, providing patients with effective alternatives to traditional surgery. These advancements not only enhance the quality of life for patients but also contribute to market growth, as healthcare providers seek to adopt the latest evidence-based practices.

Rising Prevalence of Osteoarthritis

The increasing prevalence of osteoarthritis globally is a primary driver of the Global Osteoarthritis Market Industry. As populations age, the incidence of osteoarthritis is expected to rise significantly. In 2024, the market is projected to reach 5.12 USD Billion, reflecting the growing need for effective treatments and management strategies.
 
The World Health Organization indicates that osteoarthritis affects approximately 10% of the global population over 60 years, highlighting the urgency for innovative solutions. This trend is likely to continue, with projections suggesting that by 2035, the market could expand to 13.4 USD Billion, driven by the aging demographic and the associated healthcare demands.

Emerging Markets and Demographic Shifts

Emerging markets are becoming increasingly significant in the Global Osteoarthritis Market Industry due to demographic shifts and economic development. Countries in Asia-Pacific and Latin America are witnessing rapid urbanization and an increase in life expectancy, leading to a higher prevalence of osteoarthritis.
 
As these regions develop economically, there is a growing demand for healthcare services and treatments. This trend is expected to create new opportunities for market players, as they seek to cater to the unique needs of these populations. The expansion into emerging markets could play a pivotal role in achieving the projected market growth, with a CAGR of 9.12% anticipated from 2025 to 2035.

Market Segment Insights

By Type of Osteoarthritis: Knee Osteoarthritis (Largest) vs. Hip Osteoarthritis (Fastest-Growing)

<p>The osteoarthritis market is significantly shaped by its different types, with Knee Osteoarthritis leading in market share among the segments. This dominance can be attributed to its high prevalence, especially among older demographics and those engaged in high-impact activities. Meanwhile, Hip Osteoarthritis is emerging as a fast-growing segment, driven by increasing incidence rates and rising awareness surrounding joint health. As the population ages, these market dynamics reflect a shifting focus towards effective management strategies.</p>

<p>Knee Osteoarthritis (Dominant) vs. Hip Osteoarthritis (Emerging)</p>

<p>Knee Osteoarthritis is the most prevalent type, largely impacting the quality of life and mobility for millions of sufferers. Its characteristics include pain primarily in the knee joint, stiffness, and swelling, which intensifies with physical activity. This segment benefits from various treatment options ranging from conservative management to surgical interventions, reflecting its dominant position. Conversely, Hip Osteoarthritis is gaining traction as an emerging segment, characterized by pain and stiffness in the hip joint, which can severely restrict movement. This segment's growth is supported by increased research investments, innovative therapies, and a greater emphasis on preventive care, making it a substantial area of focus for stakeholders in the osteoarthritis market.</p>

By Treatment Type: Pharmacological Treatment (Largest) vs. Non-Pharmacological Treatment (Fastest-Growing)

<p>In the Osteoarthritis Market, the treatment type segment is notably diverse, comprising pharmacological, non-pharmacological, surgical, and rehabilitation methods. Among these, pharmacological treatments command the largest market share due to their widespread usage and effective pain management capabilities. Non-pharmacological treatments are gaining traction rapidly, attributed to an increasing preference for holistic care approaches that emphasize lifestyle modifications and physical therapy.</p>

<p>Pharmacological Treatment (Dominant) vs. Non-Pharmacological Treatment (Emerging)</p>

<p>Pharmacological treatment is the dominant segment in the Osteoarthritis market, primarily comprising non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics, which provide relief to patients effectively. On the other hand, non-pharmacological treatment is emerging as a significant segment, focusing on therapies such as physiotherapy, acupuncture, and dietary management. This segment reflects a shift towards patient-centered care, emphasizing natural and lifestyle adjustments instead of relying solely on medication. As awareness of the benefits of these alternatives grows, the non-pharmacological treatment segment is expected to experience robust growth.</p>

By Severity Level: Moderate Osteoarthritis (Largest) vs. Severe Osteoarthritis (Fastest-Growing)

<p>In the Osteoarthritis Market, the distribution of market share among the severity levels reveals that Moderate Osteoarthritis holds the largest share. This segment is characterized by a significant number of patients managing chronic pain and requires ongoing treatment. Conversely, Severe Osteoarthritis, characterized by debilitating symptoms and limited mobility, has emerged as a growing segment due to increased awareness and diagnosis of severe conditions. With an aging population and rising obesity rates, these demographic factors contribute to this growth trajectory. Growth trends indicate that while Moderate Osteoarthritis remains stable in market dominance, Severe Osteoarthritis is gaining momentum as advancements in treatment options and patient management strategies evolve. The increasing prevalence of risk factors such as obesity and an aging demographic is propelling demand in this segment. Furthermore, innovative therapies and patient-centric care models are making severe treatment options more accessible, encouraging more patients to seek intervention, further boosting the segment’s growth.</p>

<p>Moderate Osteoarthritis (Dominant) vs. Severe Osteoarthritis (Emerging)</p>

<p>Moderate Osteoarthritis remains the dominant player in the severity level segment, comprising a substantial portion of the overall Osteoarthritis Market. This segment is characterized by symptoms such as joint pain, stiffness, and reduced range of motion, but patients often maintain a level of functionality, allowing for more conservative management options. On the other hand, Severe Osteoarthritis is emerging as a critical segment, driven by significant patient needs and treatment requirements. Patients in this group often experience chronic pain and functional limitations, necessitating more aggressive interventions such as surgical options and advanced therapeutic modalities. The divergence in treatment approaches for moderate and severe cases illustrates the evolving landscape of healthcare solutions available, shaped by patient demographics and treatment innovations.</p>

By Age Group: Older Adults (Largest) vs. Middle-Aged Adults (Fastest-Growing)

<p>The Osteoarthritis Market exhibits varying levels of prevalence across different age groups. Older Adults represent the largest share of the market, consistently exhibiting the highest incidence of osteoarthritis due to age-related wear and tear on joints. This demographic, typically aged 65 and above, contributes significantly to the demand for osteoarthritis treatments and management solutions as their need for pain relief and mobility enhancement continues to soar. In contrast, Middle-Aged Adults, particularly those between 45 and 64 years, showcase an increasing trend in the market as they increasingly suffer from osteoarthritis symptoms attributed to lifestyle factors, obesity, and previous joint injuries. The growth trends in the Osteoarthritis Market demonstrate a notable surge, particularly in the Middle-Aged Adults segment, which is becoming increasingly recognized as a crucial early-stage demographic for osteoarthritis treatment. This age group is driving growth as more individuals seek proactive management solutions to mitigate symptoms before they worsen. Factors fueling this upward trend include heightened awareness about joint health, increased diagnosis rates, and a growing inclination towards preventive healthcare measures, which positions them as emerging players in this market landscape.</p>

<p>Older Adults: Dominant vs. Middle-Aged Adults: Emerging</p>

<p>The Older Adults segment in the Osteoarthritis Market is characterized by a high prevalence of arthritis, primarily driven by the natural aging process, which leads to a gradual degradation of joint tissues. This segment is often associated with chronic pain and reduced mobility, prompting a strong demand for medical interventions such as pharmaceutical treatments and physical therapy options. As the population ages, this segment remains dominant, shaping market trends and product offerings significantly. Conversely, Middle-Aged Adults are emerging as a vital segment in the market, influenced by lifestyle factors such as sedentary behavior and obesity, which are contributing to earlier onset of osteoarthritis symptoms. This group exhibits a proactive approach to joint care, often seeking new therapies and products that promote joint health, thus influencing market dynamics and pushing for innovations in treatment options.</p>

Get more detailed insights about Osteoarthritis Market Research Report – Forecast Till 2035

Regional Insights

North America : Market Leader in Osteoarthritis

North America accounted for the largest share of the Osteoarthritis Market size, reaching USD 2.6 billion in 2024.
The region's growth is driven by an aging population, increasing obesity rates, and heightened awareness of osteoarthritis treatments. Regulatory support and advancements in medical technology further catalyze market expansion, with a focus on innovative therapies and patient-centric solutions. The competitive landscape is robust, featuring key players such as Pfizer, Johnson & Johnson, and AbbVie. The U.S. remains the largest market, supported by extensive healthcare infrastructure and research initiatives. Companies are investing in R&D to develop novel treatments, ensuring a dynamic market environment that addresses the evolving needs of patients and healthcare providers.

Europe : Emerging Market with Growth Potential

Europe's osteoarthritis market is valued at 1.52B, reflecting a growing demand for effective treatments. Factors such as an aging demographic, rising healthcare expenditure, and increasing prevalence of obesity contribute to market growth. Regulatory frameworks in the EU are evolving to support innovative therapies, enhancing patient access to advanced treatments. Leading countries like Germany, France, and the UK are at the forefront of this market, with a competitive landscape featuring major players like Novartis and Roche. The presence of strong healthcare systems and ongoing clinical trials further bolster the market. As companies focus on personalized medicine and biologics, Europe is set to become a key player in The Osteoarthritis.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region, with a market size of 0.88B, is experiencing rapid growth in the osteoarthritis sector. Factors such as increasing urbanization, lifestyle changes, and a rising elderly population are driving demand for osteoarthritis treatments. Governments are also implementing health initiatives to address the rising burden of chronic diseases, including osteoarthritis. Countries like Japan, China, and Australia are leading the market, with a mix of local and international players. Companies such as Amgen and Sanofi are expanding their presence, focusing on innovative therapies and partnerships. The competitive landscape is evolving, with an emphasis on research and development to meet the unique needs of the region's diverse population.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region, with a market size of 0.16B, presents unique challenges and opportunities in the osteoarthritis market. Factors such as limited healthcare access, varying economic conditions, and a growing prevalence of lifestyle-related diseases impact market growth. However, increasing awareness and government initiatives to improve healthcare infrastructure are positive signs for the future. Countries like South Africa and the UAE are leading the market, with a focus on improving treatment access and quality. The competitive landscape includes both local and international players, but the market remains underdeveloped compared to other regions. As healthcare systems evolve, there is potential for growth in innovative treatment options and patient care.

Key Players and Competitive Insights

The Osteoarthritis Market is currently characterized by a dynamic competitive landscape, driven by an increasing prevalence of the condition and a growing demand for effective treatment options. Key players such as Pfizer (US), Johnson & Johnson (US), and AbbVie (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and biologics.
 
These companies are actively pursuing partnerships and collaborations to enhance their product portfolios, thereby shaping a competitive environment that emphasizes both innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. The collective influence of these key players is significant, as they not only drive technological advancements but also set industry standards that smaller companies often follow.
 

In November Pfizer (US) announced a strategic partnership with a leading biotech firm to co-develop a novel gene therapy aimed at osteoarthritis treatment. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, indicating Pfizer's commitment to innovation in the osteoarthritis space. Such partnerships may also provide Pfizer with a competitive edge in a market that increasingly values cutting-edge solutions.
 

In October Johnson & Johnson (US) launched a new digital health platform designed to support osteoarthritis patients in managing their condition through personalized treatment plans. This initiative reflects the company's focus on integrating technology into healthcare, potentially improving patient outcomes and engagement. By leveraging digital tools, Johnson & Johnson aims to differentiate itself in a crowded market, aligning with current trends towards digitalization in healthcare.
 

In September AbbVie (US) expanded its clinical trial program for a promising new biologic therapy targeting osteoarthritis. This expansion not only underscores AbbVie's commitment to advancing treatment options but also positions the company to capture a larger market share as the therapy progresses through regulatory pathways. The strategic emphasis on clinical research and development is likely to enhance AbbVie's reputation as a leader in innovative osteoarthritis treatments.
 

As of December current competitive trends in the Osteoarthritis Market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can reliably navigate supply chain complexities while delivering cutting-edge solutions are likely to emerge as leaders in this evolving market.

Key Companies in the Osteoarthritis Market include

Industry Developments

Robexera, the first generic robenacoxib medication, will be available in 2023, according to Krka. It is intended to treat pain and inflammation brought on by soft tissue surgery and persistent osteoarthritis (OA) in dogs. A once-daily dosage schedule for Robexera, a COX2 NSAID formulation, provides anti-inflammatory pain relief2,3,4.  The medicine comes in the form of a chewable tablet with flavoring to make it easier for pet owners to administer. It comes in four strengths for ease of administering, and each pack includes a set of PIL sheets that can be converted into prescription envelopes, color-coded boxes, and perforated blisters.

The U.S. Food and Drug Administration (U.S. FDA) has granted Zydus Lifesciences final permission in 2023 to produce and distribute 50 mg/200 mcg and 75 mg/200 mcg of Misoprostol Delayed Release Tablets USP, as well as 0.5 mg and 1 mg of Varenicline tablets. Arthrotec Delayed-Release tablets are the reference listed drug (RLD) for Diclofenac Sodium and Misoprostol Delayed Release Tablets. These tablets are intended to treat rheumatoid arthritis and osteoarthritis in individuals who are at high risk of developing stomach or intestinal ulcers. According to Zydus, the medication would be produced at the group's Ahmedabad formulation manufacturing facility.

The product's annual sales in the United States were $13 million, according to the business, which cited IQVIA MAT March 2023 numbers.

September 2022: StemOne, the off-the-shelf cell therapy product by Alkem Laboratories, received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. This product is being launched in collaboration with Stempeutics, which aims to treat knee osteoarthritis, a degenerative joint disease.

August 2022: Shionogi & Co., Ltd. and Grünenthal GmbH have entered into a licensing agreement to jointly market and commercialize injectable resiniferatoxin in Japan. Resiniferatoxin is a pipeline product developed by Grünenthal, and it is intended to treat pain caused by osteoarthritis of the knee. The licensing agreement will allow the companies to bring the product to market in Japan, offering a new treatment option for patients with knee osteoarthritis.

Future Outlook

Osteoarthritis Market Future Outlook

The Osteoarthritis Market is projected to grow at a 9.12% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.

New opportunities lie in:

  • <p>Development of personalized treatment plans leveraging AI analytics. Expansion of telehealth services for remote patient monitoring. Investment in <a title="regenerative medicine" href="https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220" target="_blank" rel="noopener">regenerative medicine</a> technologies for joint repair.</p>

By 2035, the Osteoarthritis Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.

Market Segmentation

Osteoarthritis Market End Use Outlook

  • Hospitals
  • Clinics
  • Home Care
  • Rehabilitation Centers

Osteoarthritis Market Application Outlook

  • Pain Management
  • Joint Function Improvement
  • Physical Therapy
  • Surgical Intervention

Osteoarthritis Market Product Type Outlook

  • Pharmaceuticals
  • Medical Devices
  • Therapeutic Equipment
  • Nutraceuticals

Osteoarthritis Market Treatment Type Outlook

  • Non-Surgical
  • Surgical
  • Physical Therapy
  • Medication

Report Scope

MARKET SIZE 2024 5.12(USD Billion)
MARKET SIZE 2025 5.58(USD Billion)
MARKET SIZE 2035 13.37(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 9.12% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Pfizer (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Roche (CH)
Segments Covered Application, End Use, Product Type, Treatment Type
Key Market Opportunities Advancements in personalized medicine and digital therapeutics enhance treatment options in the Osteoarthritis Market.
Key Market Dynamics Rising demand for innovative therapies drives competitive forces and technological advancements in the Osteoarthritis Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Osteoarthritis Market as of 2024?

<p>The Osteoarthritis Market was valued at 5.12 USD Billion in 2024.</p>

What is the projected market size for the Osteoarthritis Market in 2035?

<p>The market is projected to reach 13.37 USD Billion by 2035.</p>

What is the expected CAGR for the Osteoarthritis Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Osteoarthritis Market during this period is 9.12%.</p>

Which companies are the key players in the Osteoarthritis Market?

<p>Key players include Pfizer, Johnson & Johnson, Novartis, and AbbVie, among others.</p>

How is the Osteoarthritis Market segmented by type of osteoarthritis?

<p>The market segments include Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Spinal Osteoarthritis.</p>

What were the valuations for Knee Osteoarthritis in 2024 and its projected value in 2035?

<p>Knee Osteoarthritis was valued at 1.54 USD Billion in 2024 and is projected to reach 4.05 USD Billion by 2035.</p>

What are the projected values for pharmacological treatment in the Osteoarthritis Market?

<p>Pharmacological treatment was valued at 1.54 USD Billion in 2024 and is expected to reach 3.92 USD Billion by 2035.</p>

How does the market perform in terms of severity levels of osteoarthritis?

The market segments by severity include Mild, Moderate, and Severe Osteoarthritis, with Moderate Osteoarthritis projected to grow significantly.

What is the market outlook for older adults suffering from osteoarthritis?

The segment for older adults was valued at 3.07 USD Billion in 2024 and is projected to reach 8.98 USD Billion by 2035.

What treatment types are included in the Osteoarthritis Market segmentation?

The market is segmented into Pharmacological Treatment, Non-Pharmacological Treatment, Surgical Treatment, and Rehabilitation.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type of Osteoarthritis (USD Billion)
    2. | | 4.1.1 Knee Osteoarthritis
    3. | | 4.1.2 Hip Osteoarthritis
    4. | | 4.1.3 Hand Osteoarthritis
    5. | | 4.1.4 Spinal Osteoarthritis
    6. | 4.2 Healthcare, BY Treatment Type (USD Billion)
    7. | | 4.2.1 Pharmacological Treatment
    8. | | 4.2.2 Non-Pharmacological Treatment
    9. | | 4.2.3 Surgical Treatment
    10. | | 4.2.4 Rehabilitation
    11. | 4.3 Healthcare, BY Severity Level (USD Billion)
    12. | | 4.3.1 Mild Osteoarthritis
    13. | | 4.3.2 Moderate Osteoarthritis
    14. | | 4.3.3 Severe Osteoarthritis
    15. | 4.4 Healthcare, BY Age Group (USD Billion)
    16. | | 4.4.1 Young Adults
    17. | | 4.4.2 Middle-Aged Adults
    18. | | 4.4.3 Older Adults
    19. | 4.5 Healthcare, BY Region (USD Billion)
    20. | | 4.5.1 North America
    21. | | | 4.5.1.1 US
    22. | | | 4.5.1.2 Canada
    23. | | 4.5.2 Europe
    24. | | | 4.5.2.1 Germany
    25. | | | 4.5.2.2 UK
    26. | | | 4.5.2.3 France
    27. | | | 4.5.2.4 Russia
    28. | | | 4.5.2.5 Italy
    29. | | | 4.5.2.6 Spain
    30. | | | 4.5.2.7 Rest of Europe
    31. | | 4.5.3 APAC
    32. | | | 4.5.3.1 China
    33. | | | 4.5.3.2 India
    34. | | | 4.5.3.3 Japan
    35. | | | 4.5.3.4 South Korea
    36. | | | 4.5.3.5 Malaysia
    37. | | | 4.5.3.6 Thailand
    38. | | | 4.5.3.7 Indonesia
    39. | | | 4.5.3.8 Rest of APAC
    40. | | 4.5.4 South America
    41. | | | 4.5.4.1 Brazil
    42. | | | 4.5.4.2 Mexico
    43. | | | 4.5.4.3 Argentina
    44. | | | 4.5.4.4 Rest of South America
    45. | | 4.5.5 MEA
    46. | | | 4.5.5.1 GCC Countries
    47. | | | 4.5.5.2 South Africa
    48. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Pfizer (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Johnson & Johnson (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Novartis (CH)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Bristol-Myers Squibb (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 AbbVie (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Amgen (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Sanofi (FR)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 GlaxoSmithKline (GB)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Roche (CH)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    4. | 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
    5. | 6.5 US MARKET ANALYSIS BY SEVERITY LEVEL
    6. | 6.6 US MARKET ANALYSIS BY AGE GROUP
    7. | 6.7 CANADA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    8. | 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY SEVERITY LEVEL
    10. | 6.10 CANADA MARKET ANALYSIS BY AGE GROUP
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    13. | 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    14. | 6.14 GERMANY MARKET ANALYSIS BY SEVERITY LEVEL
    15. | 6.15 GERMANY MARKET ANALYSIS BY AGE GROUP
    16. | 6.16 UK MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    17. | 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE
    18. | 6.18 UK MARKET ANALYSIS BY SEVERITY LEVEL
    19. | 6.19 UK MARKET ANALYSIS BY AGE GROUP
    20. | 6.20 FRANCE MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    21. | 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    22. | 6.22 FRANCE MARKET ANALYSIS BY SEVERITY LEVEL
    23. | 6.23 FRANCE MARKET ANALYSIS BY AGE GROUP
    24. | 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    25. | 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    26. | 6.26 RUSSIA MARKET ANALYSIS BY SEVERITY LEVEL
    27. | 6.27 RUSSIA MARKET ANALYSIS BY AGE GROUP
    28. | 6.28 ITALY MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    29. | 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    30. | 6.30 ITALY MARKET ANALYSIS BY SEVERITY LEVEL
    31. | 6.31 ITALY MARKET ANALYSIS BY AGE GROUP
    32. | 6.32 SPAIN MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    33. | 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    34. | 6.34 SPAIN MARKET ANALYSIS BY SEVERITY LEVEL
    35. | 6.35 SPAIN MARKET ANALYSIS BY AGE GROUP
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY SEVERITY LEVEL
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    42. | 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    43. | 6.43 CHINA MARKET ANALYSIS BY SEVERITY LEVEL
    44. | 6.44 CHINA MARKET ANALYSIS BY AGE GROUP
    45. | 6.45 INDIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    46. | 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    47. | 6.47 INDIA MARKET ANALYSIS BY SEVERITY LEVEL
    48. | 6.48 INDIA MARKET ANALYSIS BY AGE GROUP
    49. | 6.49 JAPAN MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    50. | 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    51. | 6.51 JAPAN MARKET ANALYSIS BY SEVERITY LEVEL
    52. | 6.52 JAPAN MARKET ANALYSIS BY AGE GROUP
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY SEVERITY LEVEL
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY SEVERITY LEVEL
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY AGE GROUP
    61. | 6.61 THAILAND MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    62. | 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    63. | 6.63 THAILAND MARKET ANALYSIS BY SEVERITY LEVEL
    64. | 6.64 THAILAND MARKET ANALYSIS BY AGE GROUP
    65. | 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    66. | 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    67. | 6.67 INDONESIA MARKET ANALYSIS BY SEVERITY LEVEL
    68. | 6.68 INDONESIA MARKET ANALYSIS BY AGE GROUP
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY SEVERITY LEVEL
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY AGE GROUP
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    75. | 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    76. | 6.76 BRAZIL MARKET ANALYSIS BY SEVERITY LEVEL
    77. | 6.77 BRAZIL MARKET ANALYSIS BY AGE GROUP
    78. | 6.78 MEXICO MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    79. | 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    80. | 6.80 MEXICO MARKET ANALYSIS BY SEVERITY LEVEL
    81. | 6.81 MEXICO MARKET ANALYSIS BY AGE GROUP
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY SEVERITY LEVEL
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY AGE GROUP
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY LEVEL
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY LEVEL
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY LEVEL
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF OSTEOARTHRITIS
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY SEVERITY LEVEL
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY AGE GROUP
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY TYPE OF OSTEOARTHRITIS, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY TYPE OF OSTEOARTHRITIS, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY SEVERITY LEVEL, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY SEVERITY LEVEL, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY AGE GROUP, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY AGE GROUP, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY AGE GROUP, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY AGE GROUP, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY AGE GROUP, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY AGE GROUP, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY AGE GROUP, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY AGE GROUP, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY AGE GROUP, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY AGE GROUP, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY AGE GROUP, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY AGE GROUP, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY AGE GROUP, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY AGE GROUP, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY AGE GROUP, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY AGE GROUP, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY AGE GROUP, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY AGE GROUP, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY AGE GROUP, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY AGE GROUP, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY AGE GROUP, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY AGE GROUP, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY AGE GROUP, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY AGE GROUP, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY AGE GROUP, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY AGE GROUP, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY AGE GROUP, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY AGE GROUP, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY TYPE OF OSTEOARTHRITIS, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY SEVERITY LEVEL, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY AGE GROUP, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type of Osteoarthritis (USD Billion, 2025-2035)

  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Spinal Osteoarthritis

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Pharmacological Treatment
  • Non-Pharmacological Treatment
  • Surgical Treatment
  • Rehabilitation

Healthcare By Severity Level (USD Billion, 2025-2035)

  • Mild Osteoarthritis
  • Moderate Osteoarthritis
  • Severe Osteoarthritis

Healthcare By Age Group (USD Billion, 2025-2035)

  • Young Adults
  • Middle-Aged Adults
  • Older Adults
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions